Methotrexaat Basic Pharma (Methotrexate)

Methotrexate functions as a folate antagonist. It blocks the enzyme dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition curtails the proliferation of rapidly dividing cells, including immune cells that drive inflammation and cancer cells that drive tumor growth.

The dosage of methotrexate is individualized. A qualified prescriber determines the appropriate amount, frequency and duration based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

Methotrexate is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it can be excreted in milk and may harm the infant. Effective contraception is required for women of child‑bearing potential.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexate is often considered the first‑line disease‑modifying antirheumatic drug because of its proven efficacy, oral or injectable formulations, and relatively well‑characterized safety profile. Compared with biologic DMARDs, it is less costly but may require more laboratory monitoring. Its immunosuppressive potency is similar to other conventional DMARDs such as leflunomide, yet each agent has a distinct side‑effect spectrum.

The product should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken vigorously. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow local pharmacy storage regulations and handle with aseptic technique during preparation.

Methotrexaat Basic Pharma is supplied for subcutaneous injection. A healthcare professional prepares the dose using a sterile syringe and injects it into the subcutaneous tissue, typically in the abdomen or thigh. The injection site should be rotated to reduce local irritation, and patients should be observed for any immediate adverse reactions.

Key serious risks include bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia; severe hepatic toxicity that can progress to fibrosis or cirrhosis; and pulmonary toxicity such as interstitial pneumonitis. Early detection through regular blood counts, liver function tests and monitoring for respiratory symptoms is essential to mitigate these hazards.

Methotrexate is contraindicated in patients who are pregnant, planning pregnancy, or are breastfeeding. It should also be avoided in individuals with severe renal impairment, active liver disease, uncontrolled infections, or known hypersensitivity to methotrexate or its excipients. Clinicians must assess each patient’s medical history before initiating therapy.